# Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ai-23-020-research-and-development-of-vaccines-and-monoclonal/  
Official notice: https://www.grants.gov/search-results-detail/346910

> National Institutes of Health offered grants of up to $10.0 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on June 8, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-AI-23-020 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | June 8, 2023 |
| Award ceiling | $10.0 million |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.855 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

This Funding Opportunity Announcement (FOA) solicits applications from single institutions or consortia of institutions to participate in the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network. The purpose of this FOA is to establish comprehensive, cooperative basic and translational research Centers to carry out in-depth research on prototype members of select virus families that have the potential to emerge as pandemic pathogens. The goal of these Centers will be to develop vaccine and monoclonal antibody strategies for prototype pathogen(s) that can be applied to closely related family members based on shared functional and structural properties. This FOA solicits for centers proposing research on virus families from Bunyavirales, Paramyxoviridae and Picornaviridae to be part of the ReVAMPP Network.

## Questions people ask

### Is RFA-AI-23-020 still open?

No. It closed on June 8, 2023.

### Who can apply for Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed)?

Closed June 8, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $10.0 million each.

### Who has been funded under RFA-AI-23-020?

NIH RePORTER lists 6 projects funded under RFA-AI-23-020 in fiscal 2024 to 2026, at 6 institutions. The most were at Albert Einstein College of Medicine, University of Texas Med BR Galveston, Washington University.

### Who has won Allergy and Infectious Diseases Research grants before?

The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.